Technical analysis of Grace Therapeutics, Inc. (GRCE): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage.
Price Performance
| 1 month | +0.47% |
| 3 months | -10.08% |
| Year-to-date | -38.15% |
| 1 year | -30.07% |
52-Week Range
| 52-week High | $5.18 |
| 52-week Low | $1.79 |
| Avg Volume (90d) | 240K |
Technical Indicators
| SMA 50 | $2.22 |
| SMA 200 | $3.04 |
| Beta | 0.69 |
| 30-day Volatility (annualised) | 34.6% |
| Price vs SMA 50 | -3.7% |
| Price vs SMA 200 | -29.7% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $3.16 | |
| 2025-11 | $3.18 | +0.6% |
| 2025-12 | $3.46 | +8.8% |
| 2026-01 | $3.63 | +4.9% |
| 2026-02 | $4.29 | +18.2% |
| 2026-03 | $4.63 | +7.9% |
| 2026-04 | $2.24 | -51.6% |
| 2026-05 | $2.57 | +14.7% |
| 2026-06 | $2.27 | -11.7% |
| 2026-07 | $2.08 | -8.4% |
| 2026-08 | $2.13 | +2.4% |
| 2026-09 | $2.14 | +0.5% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | $-2.53 | |
| 2026-09-14 | | $159M |
| 2026-09-14 | $-0.26 | $14M |
| 2026-09-14 | | |
| 2026-09-14 | $0.84 | $26M |
| 2026-09-14 | | |
Price
| Price | $2.14 |
| Market Cap | $35M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.75 |
| EV / EBITDA | -0.80 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 11.47 |
| Piotroski F-Score | 1 |
| Altman Z-Score | 11.56 |